Dear NBTS Community,

As we reflect on the past year, it is clear that 2022 was a year of community and growth for our organization and reconnection in the brain tumor community. Not only did our community gather in person for walks, races, and rides for the first time since the pandemic began, but we also returned to bringing the in-person experience of patient and research advocacy to the life sciences sector and biomedical innovators.

With your support, we launched the DNA Damage Response Consortium, in partnership with Yale Cancer Center, to bring world-class scientists together to work as one team with the vision of bringing forward a new class of promising treatments for adult and pediatric patients across brain tumor types. This bold collaboration combines a cross-disciplinary approach and partnerships with biopharmaceutical companies to bring results to patients faster.

Together, we raised our voices to champion the urgent, unmet needs of the brain tumor community. The total dollar amount of federal funding dedicated to brain tumor research grew by approximately $48 million in 2022 largely because of NBTS’s advocacy.

We were front and center at the reigniting of the Cancer Moonshot, an initiative by President Biden, whose son Beau succumbed to glioblastoma in 2015. As part of our nation’s efforts to reduce the cancer death rate by 50% in 25 years, NBTS stands committed to focusing on groundbreaking research initiatives with the potential to translate promising science from the lab into treatments that improve survival and quality of life for patients with brain tumors.

Engaged supporters and volunteers like you helped NBTS have a tangible impact on research and policy and expand our health and wellness services for patients and families, including the addition of a grief support group. A brain tumor diagnosis can be an isolating experience, and these support groups and personalized navigation foster conversations and show patients and care partners that they are not alone.

We want to thank all our donors, partners, supporters, advocates, and event participants. We also thank the dedicated clinicians, researchers, funders, and health care professionals who not only worked overtime during the height of the pandemic but innovated during it. You are builders, creators, catalysts, and advocates making a real difference in the lives of patients with brain tumors and their families. Together, our community is our greatest strength, and we will be the community that conquers and cures brain tumors — once and for all.

[Signatures]

Tom Roloff
Chair of the Board of Directors

David F. Arons
Chief Executive Officer
MISSION
National Brain Tumor Society unrelentingly invests in, mobilizes, and unites our community to discover a cure, deliver effective treatments, and advocate for patients and care partners.

VISION
Conquering and curing brain tumors — once and for all.

VALUES
• Patients First
• Best-in-Class Science and Service to Our Community
• Strengthened by Diversity, Equity, and Inclusion
• Relentlessly Results Driven
• Constructive, Candid, and Transparent
• Committed to Public Trust
• Collaborative and Inclusive
• Positive (Can-Do) Attitude

DEFEAT
We drive and influence best-in-class medical research to develop and deliver new innovative treatments and potential cures to patients with brain tumors as quickly as possible.

CONNECT
We convene, educate, and unite the brain tumor community.

CHANGE
We fuel the voice and power of the brain tumor community to advocate and influence public policy.
Grant aims to test drugs that target a tumor’s metabolism

NBTS AWARDED A $350,000 GRANT TO DR. PAUL MISCHEL AT Stanford University to advance new approaches to targeting the metabolism of glioblastoma (GBM) brain tumors.

The grant builds on previous findings from the Mischel lab on how the profoundly altered metabolism of GBM tumors leaves cancerous cells critically dependent on key enzymes to maintain their survival. These dependencies leave the tumor vulnerable to targeted drugs, which Dr. Mischel believes can potentially improve GBM survival rates. Dr. Mischel and his collaborators have demonstrated this through preclinical research and real-world evidence, and his collaborators will now seek to develop these existing, highly brain-penetrant drugs further and test additional treatments and combinations.

Dr. Mischel’s research will include further testing and development of the drug fluoxetine (Prozac) as a potent inhibitor of the enzyme SMPD1, which is involved in lipid metabolism and plasma membrane structure. Previous findings have shown that when given at a higher but clinically safe and achievable dose, combined with standard of care temozolomide, fluoxetine can selectively block the aggressive growth of GBMs. In addition, the team will also seek to determine whether fluoxetine can be combined with liver X receptor inhibition for an even greater potential treatment effect.

GBM is a major unmet medical need. Building on our work from [NBTS’s Defeat GBM Research Collaborative] with the goal of translating science for the benefit of patients, this integrated effort leverages an interactive and highly interdisciplinary collaboration…The strength of this grant is that it continues to follow cutting-edge science and is coupled with a development strategy that lacks the impediments that have typically held back GBM R and D.”

— PAUL MISCHEL, MD, Stanford University
Two highly experienced teams are working together to advance new drugs for the most common type of brain tumor — meningioma — with the support of a $400,000 grant from the National Brain Tumor Society, including support from Goldhirsh-Yellin Foundation and the Meningioma Research Fund in collaboration with the Brain Science Foundation.

Drs. Priscilla K. Brastianos at Mass General Cancer Center (MGH) and Harvard Medical School, along with Rachael Vaubel at the Mayo Clinic, are developing much-needed preclinical models of meningioma brain tumors. Together with expert collaborators, including NBTS board member, Dr. Eva Galanis, also from the Mayo Clinic, they will use these models to evaluate potential targeted therapies that could quickly be translated into an ongoing clinical trial.

There are currently no effective treatment options for patients diagnosed with aggressive, malignant meningiomas if surgery and radiation fail to keep the tumor in check. This research sets the stage for new, transformative treatments that could profoundly impact those living with meningioma.

Research: By the Numbers

49 SITES
in four countries are now part of an expanding GBM AGILE clinical trial evaluating three drugs

380 GBM PATIENTS
accessed advanced biomarker testing results through Project ALLELE for their diagnosis, care, and participation in clinical trials

2 RESEARCH ROUNDTABLE DISCUSSIONS
hosted by NBTS to convene experts in the field this year
NBTS Launches DNA Damage Response Consortium with Yale

Consortium convenes world-class researchers to advance an emerging class of promising treatments

NBTS LAUNCHED THE DNA DAMAGE RESPONSE CONSORTIUM, in partnership with Yale Cancer Center, in early 2022. The consortium brings together a diverse team of renowned adult and pediatric researchers and treating physicians from nine major cancer centers to rapidly advance a new class of promising potential treatments that can stop a crucial mechanism of how brain tumors grow.

The consortium will test different drugs and drug-device combinations in the laboratory, share data, and then bring the most promising investigational treatments forward to evaluate in clinical trials that match the right treatments with the right patients.

NBTS’s DNA Damage Response Consortium is propelling forward new treatments for multiple types of adult and pediatric glioma tumors, which include but are not limited to glioblastoma, oligodendroglioma, astrocytoma, ependymoma, diffuse intrinsic pontine glioma (DIPG)/diffuse midline glioma (DMG), and atypical teratoid/rhabdoid tumors (AT/RT).

The first clinical trial opened enrollment in the fall of 2022 to evaluate an investigational combination of treatments including a DNA Damage Response drug with an immunotherapy to determine if patients will realize greater survival benefit.

We always like to think that science just kind of moves at its own pace, and things kind of fall into place. One thing that I’ve learned the last 10 years running an academic lab is that actually science is all about the people. It’s the people moving the science forward...I’m incredibly thankful for the National Brain Tumor Society for actually making this happen...The goal of this consortium is to move the ball forward from the bench to the bedside and to work with pharma and biotech partners to get the drugs [into trials] using biomarker-directed approaches to get the best shots on goal.”

— RANJIT BINDRA, MD, PhD
Yale Cancer Center and Scientific Director of DDR-C

What is DNA Damage Response?

EVERY DAY, THE BODY automatically protects cells by repairing damaged DNA through a process called DNA Damage Response (DDR). Unfortunately, tumor cells are also protected by this same response, helping them survive, grow, or evolve. DDR defects in some cancers can result in uncontrolled cancer growth and evolution. These cancers still employ functioning DNA repair systems that allow these cells to survive.

Research indicates that disrupted DDR networks are possibly an ‘Achilles’ heel’ for tumors, leaving them vulnerable to a new group of treatments currently being developed.

Unlike other, more traditional precision medicine strategies, targeting tumor DDR may be applicable to virtually all malignant brain tumor types in pediatric and adult patients.

With drugs designed to attack tumors’ DDR networks already transforming the treatment of other cancers, like ovarian and breast cancer, this strategy needs to be quickly and expertly tested for patients with brain tumors. The DNA Damage Response Consortium aims to advance this emerging and promising but underdeveloped area of cancer research.
NATIONAL BRAIN TUMOR SOCIETY AND IQVIA, a leading global provider of advanced analytics, technology solutions, and clinical research services, announced a collaboration to support the development of DNA Damage Repair inhibitors for malignant brain tumors in November 2022.

“IQVIA has long been committed to making a difference for patients through collaborations with those pursuing innovative research and development of cutting-edge therapies,” said Dr. James Kyle Bryan, Chief Medical Officer, IQVIA Biotech. “This partnership extends that mindset of commitment by helping to advance these therapeutics for this vulnerable patient population.”

Partnering with an organization like IQVIA, which has extensive experience in health care and clinical trial operations, provides an opportunity to move potentially transformative treatments emerging from the world-class laboratories, within the DDR-C, into innovative clinical studies.

**NBTS RELEASED AN EPISODE OF “INFORMED IN 30”** that helps break down the concepts, key terms, and questions about the DDR Consortium with NBTS’s Chief Scientific Officer Kirk Tanner, PhD, and principal investigator Ranjit Bindra, MD, PhD, while highlighting the DDR Consortium with the help of leading experts in the field.

![Image](image.jpg)
To conquer brain tumors, strong collaboration with an active private sector is needed. To help bridge this gap — often referred to as the “Valley of Death” — between scientific discovery at academic-based institutions and commercial product development, the Brain Tumor Investment Fund raises philanthropic capital and uses the team’s expertise and experience to incentivize biotechnology, pharmaceutical, and medical device companies around the world to develop new treatments and motivate additional private financing. Thanks to generous donors who share our vision, BTIF is investing in well-qualified early-stage projects that hope to ultimately deliver transformational treatments and technologies to patients with brain tumors.

In 2022, BTIF helped propel forward into a clinical trial a potential first and best-in-class treatment approach, sonodynamic therapy, sponsored by Alpheus Medical. This innovative non-invasive approach to treatment for recurrent glioblastoma was granted both FDA Orphan Drug and Fast Track Designations to speed the regulatory review. A Phase 1 clinical trial opened patient enrollment to evaluate this approach to eradicating GBM without surgery.

BTIF Portfolio Companies
The Brain Tumor Investment Fund has developed a rigorous process to ensure that generous donations are invested in well-vetted projects and companies. BTIF is supported by a highly experienced management team to identify the best opportunities, a world-class scientific advisory council to assess the robustness of the science, and an investment committee that further conducts business due diligence.

As of 2022, the Brain Tumor Investment Fund had five companies in its portfolio:

**ALPHEUS MEDICAL**
*Product: 5-ALA/Sonodynamic therapy*
*Strategic Area: Medical Device*

**CORDANCE MEDICAL**
*Product: Focused Ultrasound System*
*Strategic Area: Medical Device*

**KINTARA THERAPEUTICS**
*Product: VAL-083*
*Strategic Area: DNA Damage Response*

**MODIFI BIO**
*Product: KL-50*
*Strategic Area: DNA Damage Response*

**TELO THERAPEUTICS**
*Product: TSM1001*
*Strategic Area: Precision Oncology*
NBTS ENSURES THE BRAIN TUMOR COMMUNITY’S NEEDS are reflected in national medical research and health care policy. Together, with more than 18,000 advocates across all 50 states, we advocate for the federal government to increase federal funding for brain tumor research, improve the adequacy, affordability, and access of health insurance for people living with a brain tumor, reduce health disparities, and raise national awareness of the brain tumor community’s treatment and quality of life needs.

NIH increases brain tumor research funding by $20M

DUE TO NBTS’S ADVOCACY EFFORTS IN COLLABORATION with the brain tumor community, NIH funding for brain tumor research increased by $20 million to $435 million in 2022.

“Policymaking is what is going to make the biggest difference. You have to advocate for money and push for the research for the government to increase funding. It’s important for policymakers to understand that this brain tumor community needs help.” — Jyothi

IN FEBRUARY 2022, NBTS WAS HONORED TO REPRESENT THE millions of Americans impacted by brain tumors every year at a White House event to reignite the Cancer Moonshot. NBTS board of directors member Dr. Edjah Nduom, a renowned neurosurgeon who introduced President Biden at the event, and NBTS CEO, David Arons, attended.

Congress reauthorizes the Childhood Cancer STAR Act

THE CHILDHOOD CANCER STAR ACT — the most comprehensive childhood cancer legislation taken up by Congress in decades — was signed into law in 2018 to advance pediatric cancer research and child-focused cancer treatments, improve childhood cancer surveillance, and provide enhanced resources for survivors and those impacted by pediatric cancer. Members of the Senate and House introduced a bipartisan bill to reauthorize the STAR Act beyond its set expiration in 2023 and extend these important programs.

More than 200 NBTS advocates supported its reauthorization during their in-district congressional meetings in the fall. At year end, Congress passed the reauthorization of the Childhood Cancer STAR Act and provided $30 million to fully fund its initiatives in 2023.
With the support of a bipartisan Congress, the GBM Awareness Day resolution passed earlier than ever, tripling the number of co-sponsors in the House to 13 representatives.

NBTS commemorated GBM Awareness Day on July 20, 2022, with an in-person reception in Washington, D.C. Members of Congress, patients, care partners, researchers, and other members of the brain tumor community gathered to shine a spotlight on glioblastoma — the most common, complex, treatment-resistant, and deadliest type of brain cancer.

“Thanks so much for giving me the opportunity to speak at the GBM Awareness Day reception and also share my story on NBTS’s website. This experience has been very therapeutic and a rush of emotions. I’m so glad that I did it, and the event was great.” — Lisa C.

△ U.S. Congressman Jake Auchincloss (MA) spoke about the importance of elected officials highlighting this deadly disease through bipartisan action.

“Thanks so much for giving me the opportunity to speak at the GBM Awareness Day reception and also share my story on NBTS’s website. This experience has been very therapeutic and a rush of emotions. I’m so glad that I did it, and the event was great.” — Lisa C.

“I’m so glad that I did it, and the event was great.” — Lisa C.
NBTS EQUIPS PATIENTS AND CARE PARTNERS with tools and resources to navigate every step of their unique health care experience — from understanding their diagnosis and building their medical team to making decisions about treatment, including accessing clinical trial opportunities and palliative care.

For patients and care partners with a rare disease like a brain tumor, it can be an isolating experience. NBTS’s virtual Brain Tumor Support Conversations (BTSC) and Grief Support Conversations, launched in 2022, help foster connections within the brain tumor community, showing patients and care partners that they are not alone.

“I learned about NBTS one year ago when I was looking for resources to help deal with the unexpected loss of a loved one due to a brain tumor. I always look forward to attending each of the NBTS groups [Brain Tumor Support Conversations, Meditation Mondays, and Grief Support Conversations], as they have been an important part of my journey. A brain tumor diagnosis can come as a shock to those who are impacted. All of the group leaders’ lives have been touched by brain tumors, so they have a unique understanding of what the journey can be like. With each NBTS group, I experience a sense of community and healing. They do an excellent job of providing support for people facing such a difficult experience.” — Mala U.

Each month, moderators help facilitate NBTS programming in support of the brain tumor community: Tori Best (Meditation Mondays and NBTS Associate Director of Community), Lisa O’Leary and Adam Hayden (Brain Tumor Support Conversations), Rachael Kittleson (NBTS Senior Director of Community), and Holly Gainsboro (Grief Support Conversations).
“I absolutely love participating each month in the Brain Tumor Support Conversations because everyone seems like me. It’s not like going to the local pool where everyone is enjoying life and appears carefree, while I feel like an alien because none of these people experience what I’ve experienced. Brain Tumor Support Conversations is like a family. I could mention something, and everyone’s head is nodding. I’m like, ‘Wow, everyone gets me.’” — Kymberlee B.

“I first learned about NBTS when my father started a fundraiser after my diagnosis. I wasn’t able to find a support group that clicked locally, and when looking online, I thought of NBTS and found Brain Tumor Support Conversations. For me, it’s been a space that pulls out the more vulnerable parts of myself and confronts them in the group. Brain Tumor Support Conversations and Meditation Mondays create healthy outlets for processing the reality of brain tumors. They open doors for people to explore what a brain tumor means to them, which may not be as accessible elsewhere.” — Matt D.

“Meditation is a centering and calming approach to the hectic day-to-day challenges for caregivers and those of us going through treatments, side effects from surgery, and the life-changing impact that brain cancer causes. Each month, we look forward to sharing time with Tori Best, the host of Meditation Mondays, to decompress from the anxieties of everyday stress with a group sharing the same unfortunate disease.” — Louise H.
“I’m a fixer. I cannot fix that Julio has brain cancer, which is a difficult pill to swallow sometimes. It’s really helpful to talk to people who understand exactly what you’re dealing with at Brain Tumor Support Conversations, even if they don’t have advice for you. Because even with different types of brain tumors, or ages, there are certain things that we all deal with.”

— Liz P.
TOP FUNDRAISING INDIVIDUALS

Race for Hope DC:
Katherine Savits – $72,863

National Brain Tumor Ride:
Bill Coffman – $31,523

Northern California Brain Tumor Walk and Race:
Penny Rix – $26,760

New England Brain Tumor Walk:
Brett Johnson – $24,968

Carolina Brain Tumor Walk and Race:
Tucker Windle – $21,750

Virginia Brain Tumor Walk and Race:
Josh Spain – $15,035

Colorado Brain Tumor Walk and Race:
John Klitzke – $14,686

Race for Hope PA:
Lynn Oxenberg – $13,525

New York Brain Tumor Walk:
Eric Alper – $9,535

New Jersey Brain Tumor Walk and Race:
Rachel Windman – $7,949

Southern California Brain Tumor Walk and Race:
Susan Mahoney – $5,609

TOP FUNDRAISING TEAMS: $100,000+

Rachel’s Racers: $191,464

Team E: $161,759

TOP FUNDRAISING TEAMS: $50,000+

Remarkable Strides: $78,604

Lisa’s Riders: $71,322

Survivors: $62,561

Team Oligo: $51,522

RACE FOR HOPE DC
“Three months into my treatment for glioblastoma, I learned about the Race for Hope from a friend. I needed something positive to help me through a very difficult time. From my first exhilarating race day experience until today, the Race for Hope has been the silver lining in a very dark cloud. Eleven years later, it now serves as my gratitude celebration and a way for me to celebrate the miracle of surviving and thriving another year against the odds. Each year I dedicate my Race to the family members and friends I have lost to brain cancer, a list that is painfully growing. I’m dedicated to doing my part to making more miracles happen and the Race for Hope makes that possible.” — Karen T.

RACE FOR HOPE PHILADELPHIA
“Katie specifically asked that we continue our participation in Race for Hope Philadelphia in the hopes one day no family would have to endure what she and our family did during the 17 months of her battle with DIPG. I am a proud member of NBTS, having directly contributed to supporting the worthwhile mission of NBTS by raising over $250,000 [over the years] in memory of the brave, beautiful, and brilliant Katie.” — Denise B.
Signature Events

TOP FUNDRAISING TEAMS: $25,000+

David Cook’s Team for a Cure: $46,553
Rabbi’s Runners: $44,210
Friends of Carol Welsh - Super Survivor: $40,108
Valero Gray Z’s: $33,899
Team Mawn: $33,612
Sharing Hope: $32,641
Team Coffman: $32,479
Team Incredibles: $30,591
Spain’s Brain Train: $28,697
Team Bald Bubby: $28,579
Mac Challenge: $27,011
Maryland Brain Tumor Treatment & Research Center: $25,413

TOP 10 RECRUITING TEAMS

Rachel’s Racers: 233 team members
TEAM E: 213 team members
Noëlle’s Symphony: 101 team members
David Cook’s Team for a Cure: 90 team members
Quentin’s Testimony: 82 team members
Andrew’s Hulkamaniacs: 82 team members
Team PR: 74 team members
Steph Strong: 71 team members
Survivors: 69 team members
Team Dunn Second To None: 63 team members

NATIONAL BRAIN TUMOR RIDE
“I rally behind the cause to ride for our family and friends who have lost their loved ones. You have moments in training or on the ride when you don’t want to keep moving forward and feel done. When I push through that, it’s a way to remember them and honor what they had to go through.” — AJ C.

NORTHERN CALIFORNIA BRAIN TUMOR WALK AND RUN
“It’s nice to be in the community of other brain tumor patients at the walk — hear people’s stories, offer support, and receive the support, too. The need for research is urgent. I feel like I have a part to play in this, so I try to raise funds and stay involved with the community.” — Craig F.
Fundraise Your Way
Top Fundraising Events

$50,000+
- Team Billy Ride and Walk for Research: $102,190
- Jeff Dropo Run 4 Kids in Honor of Brad White: $100,000
- Fight for the Brain Happy Hour: $77,477
- This is Howie Roll ACAC Fitness Fundraiser: $62,117
- Madison Brain Tumor 5K: $60,459

$25,000+
- Jones’n for a Cure Golf Tournament: $45,142
- Play Hurt Project: $40,463
- Childhood Brain Cancer Research Collaborative Golf Tournament: $40,000
- 50 Miles in 31 Days Challenge: $37,862
- Alston Construction Brain Tumor Awareness Month Fundraising: $37,031

$10,000+
- P&D Student Choreography Project: $24,928
- Molly and Claire Lindenbach’s “Lemon-Aid” Stand for Dad: $23,187
- Dips for Di: $23,147
- Tumor Takedown Tailgate: $21,974
- Franklin’s Fairway Golf Tournament: $20,212
- Florida Eagle Riders Events: $20,000
- Tavino Strong 10K: $19,864
- Go Gray in May 5K for Brain Tumor Awareness: $19,309
- Anthony (A.) Paul Filiberto GBM Awareness Day Fundraiser: $18,512
- Mimosa March to Cure Brain Cancer: $18,165
- An Evening to Support Brain Cancer Research: $17,257
- Bob Burns Memorial 5K: $15,000
- Michael Cassidy Shamrock ‘N’ Run: $15,000
- Run 4 Dray: $15,000
- May Humors for Brain Tumors: $14,827
- First Annual Community Fundraiser: $13,992
- Epicest Golf Tournament: $13,068
- Adam’s Annual Brain Fest: $12,676
- Gandython: $12,399
- Joggin’ 4 the Noggin: $11,000
- Tom Goff Memorial Golf Tournament: $10,255
- Aaron Takes Action: $10,000
- GBM Foundation Events: $10,000
- True Blue Shootout for a Cure Lacrosse Tournament: $10,000

— “Losing my brother to a brain tumor made me feel helpless. Channeling my energy to a yearly fundraiser in his memory has been cathartic because it feels like we’re truly doing good by raising funds to find a cure. Hopefully, one day, the research that we’re helping fund will save another family from going through a similar experience of losing someone to brain cancer.”
— Sara L., Gandython

— “It has always been our goal, from day one of the Jeff Dropo Run 4 Kids, to make a difference for all cancer patients, young and old, and their loved ones who currently battle, or have battled cancer in their lifetime. With the National Brain Tumor Society’s partnership, we can continue building on this goal making it even more effective to touch more lives in the fight for better treatments, better quality of life, and more cures.”
— Kathie P., Jeff Dropo Run 4 Kids in Honor of Brad White

— “The annual events, like our golf outing, allow us an opportunity to bring the community around us together to support our mission. The growth of the tournament over the past few years has allowed us to truly impact the research being directed toward pediatric brain cancer and impact local families in our community that are navigating a diagnosis. What stemmed from a personal mission of our team members has transformed into an event which continues to deliver on our mission, year after year.”
— Rich D. and Alex B., Childhood Brain Cancer Research Collaborative Golf Tournament
$20,000+
Gail Flanigan - TCS New York City Marathon: $38,501
Mike Squillante - Boston Marathon: $32,286
Bryan Wiler - 41 for 41 Challenge: $22,355

$10,000+
Jim Proferes - TCS New York City Marathon: $16,894
Nicole Cutler - Boston Marathon: $16,505
Ryan Tsang - United Airlines NYC Half: $14,845
Frank Martire - United Airlines NYC Half: $11,814
Sarafina Klopfen - TCS New York City Marathon: $11,701
Casey McCarthy - United Airlines NYC Half: $11,527
Kristen Connelly - TCS New York City Marathon: $11,290
Katie Kurz and Andrea Rubio - “Cheer for Caroline,” Milano Marathon and Ironman World Championship: $13,700
Ashley Vincent - Boston Marathon: $10,866
Ronald Clark - ASICS Falmouth Road Race: $10,830
Paul Fleming - “Battle with Barbara,” Ironman Mont-Tremblant: $10,736
Jason Reeder - “Easton Strong,” Chattanooga 70.3 Ironman: $10,121

$5,000+
Laura Hurvitz - TCS New York City Marathon: $9,791
Trevor Theunissen - United Airlines NYC Half: $9,696
Olivia Tangney - Beantown Marathon: $9,520
Denise Nolan - ASICS Falmouth Road Race: $9,167
Tommy Mizwicki - Medtronic Twin Cities 10 Mile: $8,897
Janna Armstrong - TCS New York City Marathon: $8,673
Alex Muench - TCS New York City Marathon: $7,862
Dana Jachi - United Airlines NYC Half: $7,241
Maggie Gallagher-Lilly - TCS New York City Marathon: $6,689
Jennifer Ciufo - TCS New York City Marathon: $6,743
Bradford Yankiver - United Airlines NYC Half: $6,580
Zachary Herrmann - 100 Miles to Help: $6,502
Elliot Engelstein - TCS New York City Marathon: $6,389
Nikki Ferrara - TCS New York City Marathon: $6,277
Samantha Ludwig - TCS New York City Marathon: $6,238
Monique Ciricello - Boston Marathon: $5,781
Daniel Friedman - TCS New York City Marathon: $5,740
Catherine Altieri - TCS New York City Marathon: $5,656
Megan Gebert - ASICS Falmouth Road Race: $5,339
Dan Marean - Newport Marathon: $5,401
Run For Chase - TCS New York City Marathon: $5,393
Lily Flood - TCS New York City Marathon: $5,355
Peter Steenland - TCS New York City Marathon: $5,339
Kathy DeGiulio - Glass City Marathon: $5,290
Ryan McCormick - TCS New York City Marathon: $5,024

“Being a Gray Nation Endurance athlete has given me the opportunity to do something I enjoy and do it for a purpose — to find a cure. Joining a team with like-minded people who have similar values is a motivation that is difficult to put into words. If I hadn’t met this team at the beginning of the year, I’m not sure where I would be today.”
— Michael S., Boston Marathon

“[Tom] and I talked for years about completing the Appalachian Trail (AT) in sections, but glioblastoma had other ideas. Nineteen months later, Tom was gone at just 36 years old. Early in 2022, I started thinking about a trail run on the AT. The route is approximately 41 miles long, and Tom would have turned 41 this year. That sealed it. I immediately decided I needed to complete the run in his honor, raising funds for NBTS in the process.”
— Bryan W., 41 for 41 Challenge

“Being a GNE athlete means the world to me. Not only was I able to give back to NBTS, but I could do this by running a marathon — a seemingly insurmountable feat that I never thought I’d be capable of when I was in recovery — with a community of athletes who have shared my struggles in some form.”
— Kayla S., NYC Marathon
CORPORATE PARTNERS

$100,000+
Bayer Pharmaceuticals
Bristol Myers Squibb
Danaher
IQVIA
Novocure

$50,000+
Genentech
GT Medical Technologies
Menarini Stemline Therapeutics

$25,000+
Chimerix
Cravath, Swaine & Moore
Kiyatec
Le-Vel Brands
Northern Bank
Servier Pharmaceuticals
ShopRites of Zallie Family Markets
Showalter Construction Company, Inc.
Stryker Corporation
University of Maryland - Neurosurgery
Valero Energy Corporation

$10,000+
ADT
Abcuro, Inc.
Crosby Hop Farm, LLC
Geico Philanthropic Foundation
Gerald J. Glasser Brain Tumor Center Atlantic Health System
Highland Yard
Jefferson Health
Karyopharm Therapeutics
Kintara Therapeutics
Mass General Brigham
Medexus Pharma
NYU Langone Health Laura and Isaac Perlmutter Cancer Center
Penn Medicine
Raymond James Financial, Inc.
Wharf Hospitality Group

“Brain cancer patients and their families exhibit strength and courage throughout their journey. It’s a privilege to support organizations like NBTS that are working to find a cure. In 2022, we got moving for the cause by hosting a Go Gray in May 5K and a month-long step challenge. The partnership between NBTS and Stryker continues to spread awareness of the disease while reinforcing our shared vision of providing better patient outcomes.” — Jeff Gorton, vice president and general manager of Stryker’s Neurosurgical business

FOUNDATION PARTNERS

$100,000+
Rally Foundation for Childhood Cancer Research and The Truth 365
Robert Connor Dawes Foundation
The Sontag Foundation
StacheStrong
The Stringer Foundation

$25,000+
GLK Foundation
KM Legacy Foundation
Students Supporting Brain Tumor Research (SSBTR)

$10,000+
Gilbert Memorial Fund
James and Deborah Burrows Foundation
John and Maria Laffin Trust
Leonard & Hilda Kaplan Charitable Foundation
Pray for Gray Foundation

“The Gwen L. Kosinski Foundation is proud to work with NBTS on all levels. The resources, knowledge, and connections that NBTS provides to smaller, regional organizations such as ours, allows our foundation to be part of leading medical research all over the country. GLK’s involvement in the NBTS Defeat GBM Collaborative is one of our greatest honors as a brain tumor research foundation.” — GLK Foundation
Individual Donors

VISIONARY SOCIETY
($250,000+ CUMULATIVE GIVING SINCE 2008)
Anonymous (5)
The Claey Family
Stephen and Ellen Conley
The Corkin Family
Ashley and Alan Dabbiere
Susan and Jeff Davis
The Hamill Family
The Hankin Family Charitable Foundation
Sandra and Mark Kramer
Sally and Steven Lamb
Michael and Dawn Nathanson and Family
The Sadler Family
Bob and Deborah Newman Sharpe
Judi Rotenberg Ross Zuker and Edward Zuker

CIRCLE OF CHANGE ($25,000+)
Anonymous
The Claey Family
Stephen and Ellen Conley
Estate of Jean Cooper
Diana and Matthew Gordon
The Hankin Family Charitable Foundation
The Hsu Family
Sandra and Mark Kramer
Estate of Rufus Thomas Long
Estate of Carol S. O’Dore
Waleed Ramadan
Estate of Dorothy M. Ramsey
The Sadler Family
Bob and Deborah Newman Sharpe
Richard Wells

CIRCLE OF PROGRESS ($10,000 - $24,999)
Harold Anderson
Anonymous (4)
Brian Bennett
Allison Brooks
Christopher Brown
Marilyn Cassidy
James and Peggy Conley
Jim Cooper
Teri Day
Sarah Durham and Craig Winer
Marcie Feldman
Tiffani Fry
Matthew Gibbons
Amy and Steven Halvorsen
Leonard Hyde
Stephanie James
Lindsay and Deborah LaRoche
Chauho Leung
Robert Matthews
Kim and Jay Nadler
Sara Naison-Tarajano
Jim Nichols
Marta Ann Peterson
Scott Rakestraw
Benjamin Rockwell
Tom and Michelle Roloff
Samuel Ross
Nick Rossi
Larry Saliterman
Katherine Savits
Anthony Scaramucci
Estate of Linda L. Sellaro
David S. Stone Foundation
Kelly and Aaron Theberge
Catherine Wytzka
Judi Rotenberg Ross Zuker and Edward Zuker

Supporters gathered in Aspen, Colorado, in July 2022 to recognize cutting-edge glioblastoma research made possible by the Sharpe-NBTS Brain Cancer Research Awards. From left to right: Dr. Tim Cloughesy, Dr. Annick Desjardins, Dr. Maria Bishop, Deborah Sharpe, Dr. Dino Stea, Dr. Patrick Wen, David Arons, and Dr. Susan Chang
BOARD OF AMBASSADORS

*Members of the Board of Ambassadors serve through volunteering leadership, expertise, and philanthropic support to NBTS.*

Christopher Brown  
Mariana César de Sá  
Ricardo César de Sá  
Jim Clarahan  
Jim Cooper  
Stephen C. Conley  
Michael Corkin  
Susan and Jeff Davis  
Julie and Michael Durbin  
Diana and Matthew Gordon  
Jim Graul  
Deborah and Lindsay LaRoche  
Robert Matthews  
Michael Nathanson  
Lido Ramadan  
Chris Suplick  
Aaron and Kelly Theberge  
Meghan Whaley

“We are proud to serve on the NBTS Board of Ambassadors because our lives have been personally touched by a loved one who passed away from this illness. We are committed to helping NBTS find new treatments so that other families can have more time with their loved ones.”  
— Drs. Diana and Matthew Gordon

CATALYST CIRCLE

*Members of the Catalyst Circle have made leadership gifts in support of the Nathanson Family Catalyst Fund for Brain Tumor Research: NathansonFund.org.*

Amy Null and Andrew Budson  
Andrew Merken  
Jeanie and Jim Kirkiles  
Judi Rotenberg Ross Zuker and Edward Zucker  
Martin Bicknell Household  
Julie and Michael Durbin  
Michael and Dawn Nathanson  
The Corkin Family  
Michael Goss  
Ronald Rubin  
Sarah Durham and Craig Winer  
The Sadler Family  
Lowenstein Sandler LLP  
Sentinel Benefits and Financial Group  
Shikiar Family Foundation

“Our mom used to always quote the saying, ‘To whom much is given, much is expected.’ For our family, we were fortunate to be in a position where we have funds to support causes across different priorities. We want advancements in glioblastoma to be a key part of our family’s philanthropic plan and to feel like our funds are actually able to help move the dial.”  
— Jennifer H. and Stephanie S.
Board Members

ACTIVE VOTING BOARD MEMBERS
Erica Birke
Allison Bishof
Dave Brown, Treasurer
Robert Burger, Vice Chair
Rob Corrao
Evanthia Galanis, MD
Adam Hayden
Ryan Lang
Frank Macchiarola
Edjah Nduom, MD
Eric Olson, PhD
Mil Parekh
Leah Recht, JD
Tom Roloff, Chair
Liz Salmi, Clerk
Kabir Sethi
Joohee Sul, MD
Corie Yutkin
Salo Zelermyer, JD
Bonnie Feldman, Non-Voting Co-Founder

ACTIVE NON-VOTING EMERITUS BOARD MEMBERS
Cord Schlobohm, DMD
Sheila Killeen
Michael Corkin
Ken Grey
Susan Pannullo, MD
Rick Genderson
Rabbi Eric Wisnia
Michael Nathanson, JD

NBTS ran a year-end campaign to raise critical funds to break down barriers today and forge opportunities to transform brain tumor research and health care for the future. One of the two video profiles featured Liz Salmi, who serves as the clerk of the NBTS board of directors. Liz and her husband Brett spoke about living with her grade 2 astrocytoma diagnosis for 15 years and how their experiences led them to champion breakthroughs ahead.

“Through the National Brain Tumor Society, I work with patient advocates, clinicians, researchers, and care partners in the co-design of research, and I am able to bring my voice directly to leaders who have voting power and decision-making power about how science dollars are spent.” — Liz Salmi

Adam Hayden — NBTS board member, advocate, fundraiser, organizer, and co-facilitator of NBTS’s Brain Tumor Support Conversations — received the Jan Esenwein Public Service Award at the 2022 Society of Neuro-Oncology Conference for his contributions to the field of neuro-oncology.

“As a long-time and committed NBTS advocate and now a member of its Board of Directors, I’ve been exposed to NBTS priorities and the good we do to invest in, unite, and mobilize the brain tumor community. Attending the Society for Neuro-Oncology Annual Meeting punctuated the influence and value that NBTS offers the brain tumor community. From the reception to speakers and presentations, those excited to meet with NBTS Chief Scientific Officer, Kirk Tanner, and the crowd swirling around the NBTS booth in the Exhibit Hall, it is abundantly clear that NBTS is transforming the brain tumor landscape.” — Adam Hayden

WATCH VIDEO
National Brain Tumor Society unrelentingly invests in, mobilizes, and unites our community to discover a cure, deliver effective treatments, and advocate for patients and caregivers. We advance our mission through three interconnected, programmatic strategies: Defeat, Connect, and Change. 84% percent of funds raised by NBTS goes directly to advancing our programs.
National Brain Tumor Society takes great pride in our financial efficiency and accountability, and we work to maximize the value of every dollar we receive. The GuideStar Platinum Seal of Transparency is the highest level of recognition offered by the organization. As this designation demonstrates, we are committed to transparent communication and responsible stewardship of donor investment.